Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
Type:
Grant
Filed:
August 5, 2020
Date of Patent:
April 12, 2022
Assignee:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
Abstract: An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.
Type:
Application
Filed:
October 14, 2021
Publication date:
February 3, 2022
Applicant:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Adel PENHASI, Avi Avramoff, Maxim Gomberg, Valerie Azoulay
Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
Abstract: A depot system containing at least one antibiotic and a biodegradable poly(ester-anhydride) of ricinoleic acid (RA) and sebacic acid (SA) having alternating or semi-alternating ester and anhydride bonds is provided. The system provides prolonged local release of the antibiotic at the site of injection while maintaining the systemic antibiotic levels at sub-therapeutic concentrations.
Type:
Grant
Filed:
March 29, 2017
Date of Patent:
October 12, 2021
Assignee:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
Abstract: Composition and methods suitable for treating Helicobacter infection and diseases associated therewith are provided. The composition containing fusidic acid or a pharmaceutically acceptable salt or solvate thereof.
Abstract: An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
Type:
Application
Filed:
August 5, 2020
Publication date:
January 14, 2021
Applicant:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Abraham J. DOMB, Michael GRISHKO, Ezra HANUKA, Ron SCHLINGER, Tal HAGIGIT
Abstract: Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.
Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.
Type:
Grant
Filed:
December 17, 2015
Date of Patent:
September 15, 2020
Assignee:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Abraham J. Domb, Michael Grishko, Ezra Hanuka, Ron Schlinger, Tal Hagigit
Abstract: A composition suitable for forming a viscous suspension upon admixing with an aqueous medium, methods for its production and use thereof are provided. The composition includes a plurality of units, each unit having a core containing a proton pump inhibitor and an outer coating containing a gel-forming agent.
Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Abstract: An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.
Type:
Application
Filed:
September 3, 2017
Publication date:
July 11, 2019
Applicants:
DEXCEL PHARMA TECHNOLOGIES LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.
Type:
Application
Filed:
January 4, 2019
Publication date:
May 2, 2019
Applicant:
DEXCEL PHARMA TECHNOLOGIES LTD.
Inventors:
Tomer GOLD, Ron SCHLINGER, Yochai Yakovson